Table 1.
Efficacy of SARS-CoV-2 vaccine on Clinical trials.
| SARS- CoV-2 variant | Key mutations | First detected | Transmissibility | Vaccine-mediated protection | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Corona Vac (Sinovac) | NVX- CoV2373 (Novavax) | mRnA-1273 (moderna) | Ad26.CoV2-S (Johnson & Johnson) | AZD1222 (AstraZeneca– university of oxford) | BnT162b2 (Pfizer– BionTech) | References | ||||
| Wuhan strain | Reference strain | China, December 2019 | Original strain | 50–90% | 89% | 94.1% | 66% | 55–81% | 95% | Rahimi et al., 2021 |
| B.1.617.2 (Delta) | L452R | India, December 2020 | 97% increase | Not known | Not known | Neutralization titer 6.8-l | Reports of 60% effectiveness | 92% effective against hospitalization | one dose of vaccine is 88% effective | Tregoning et al., 2021 |
| T478K | ||||||||||
| D614G | ||||||||||
| P681R | ||||||||||
| Alpha, B.1.1.7 | H69/V70 deleti | UK, September 2020 | ~50% increase | Unknown | 86% | 2.3–6.4 in titres of neutralizing antibodies | 70% | 75% | 90% | Wang et al., 2021; Abu-Raddad et al., 2021 |
| Beta, B.1.351 | D614G | South | 25% increase | Unknown | 60% | Reduced levels of neutralizing antibodies | 72% efficacy in the USA, and 57% in South Africa | 10% | 75% | Hoffmann et al., 2021 |
| K417N | Africa, | |||||||||
| E484K | September 2020 | |||||||||
| N501Y | ||||||||||
| Gamma, P.1 (B.1.1.28.1) | E484K | Japan/ | 1.4–2.2 times more transmissible | 51% | Unknown | Reduced levels of neutralizing antibodies | 68% | Unknown | No evidence of reduced protection | Aleem et al., 2021 |
| K417N/T | Brazil, | |||||||||
| N501Y | December 2020 | |||||||||
| D614G | ||||||||||